Miriam Cuatrecasas

Dr. Miriam Cuatrecasas

Hospital Clinic of Barcelona
+1
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2012 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
ESEster Sanchez-Tillo
Ester Sanchez-Tillo
YLYongqing Liu
Yongqing Liu
OBOriol de Barrios
Oriol de Barrios
LSLaura Siles
Laura Siles
LFLucia Fanlo
Lucia Fanlo
APAntonio Postigo
Antonio Postigo

26 April 2010 in Oncogene
Verified
Journal Article
Closed access
ESEster Sanchez-Tillo
Ester Sanchez-Tillo
ALA Lázaro
A Lázaro
RTR Torrent
R Torrent
Miriam CuatrecasasMiriam Cuatrecasas
Miriam Cuatrecasas
EVE C Vaquero
E C Vaquero
APA Postigo
A Postigo

11 November 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ESEster Sanchez-Tillo
Ester Sanchez-Tillo
OBOriol de Barrios
Oriol de Barrios
LSLaura Siles
Laura Siles
Miriam CuatrecasasMiriam Cuatrecasas
Miriam Cuatrecasas
ACAntoni Castells
Antoni Castells
APAntonio Postigo
Antonio Postigo
In most carcinomas, invasion of malignant cells into surrounding tissues involves their molecular reprogramming as part of an epithelial-to-mesenchymal transition (EMT). Mutation of the APC gene in most colorectal carcinomas (CRCs) contributes to the nuclear translocation of the oncoprotein β-catenin that upon binding to T-cell and lymphoid enhancer (TCF-LEF) factors triggers an EMT and a proinvasive gene expression profile. A key inducer of EMT is the ZEB1 transcription factor whose expression promotes tumorigenesis and metastasis in carcinomas. As inhibitor of the epithelial phenotype, ZEB1 is never present in the epithelium of normal colon or the tumor center of CRCs where β-catenin remains membranous. We show here that ZEB1 is expressed by epithelial cells in intestinal tumors from human patients (familial adenomatous polyposis) and mouse models (APC Min/+ ) with germline mutations of APC that result in nuclear accumulation of β-catenin. However, ZEB1 is not expressed in the epithelium of hereditary forms of CRCs that carry wild-type APC and where β-catenin is excluded from the nucleus (Lynch syndrome). We found that β-catenin/TCF4 binds directly to the ZEB1 promoter and activates its transcription. Knockdown of β-catenin and TCF4 in APC -mutated CRC cells inhibited endogenous ZEB1, whereas forced translocation of β-catenin to the nucleus in APC -wild-type CRC cells induced de novo expression of ZEB1. Upregulation of MT1-MMP and LAMC2 by β-catenin/TCF4 has been linked to invasiveness in CRCs, and we show here that both proteins are activated by ZEB1 coexpressing with it in primary colorectal tumors with mutated APC . These results set ZEB1 as an effector of β-catenin/TCF4 signaling in EMT and tumor progression.

1 September 1998 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
WGW L Gerald
W L Gerald
MLM Ladanyi
M Ladanyi
ENRIQUE DE ALAVAENRIQUE DE ALAVA
ENRIQUE DE ALAVA
Miriam CuatrecasasMiriam Cuatrecasas
Miriam Cuatrecasas
BKB H Kushner
B H Kushner
JRJ Rosai
J Rosai
PURPOSE: Intense investigation has reshaped concepts about undifferentiated tumors occurring in young people (small round-cell tumors). Tumors associated with t(11;22)(p13;q12) and descriptively designated desmoplastic small round-cell tumor (DSRCT) are a distinctive, rare, poorly understood member of this family. We reviewed 109 cases of DSRCT to further characterize this entity better. METHODS: Clinical information and histology were reviewed. Immunohistochemistry and immunoblotting were performed using standard techniques. Chimeric EWS-WT1 RNA and DNA were detected by polymerase chain reaction (PCR) and genomic translocation breakpoints mapped in a subset of cases. RESULTS: There were 90 males and 19 females from 6 to 49 years of age (mean, 22 years). A total of 103 had tumor in the abdominal cavity, four in the thoracic region, one in the posterior cranial fossa, and one in the hand. Typical histologic and immunohistochemical features were usually evident in well-sampled tumors, but variations in cellularity, stromal components, cytology, architecture, and immunoreactivity occurred. Tumor cells were usually reactive with antibodies to keratin (67 of 78 cases, 86%), epithelial membrane antigen (50 of 54, 93%), vimentin (64 of 66, 97%), desmin (70 of 78, 90%), neuron-specific enolase (60 of 74, 81%), and the EWS-WT1 chimeric protein (25 of 27, 93%); typically nonreactive for muscle common actin (one of 58, 2%), myogenin (zero of eight, 0%), and chromogranin (one of 46, 2%); and variably reactive for MIC2 (nine of 47, 20%) and p53 (five of 17 with > 20% tumor cells reactive). Functional EWS-WT1 gene fusion was evident in 25 of 26 cases with genomic breakpoints in WT1 intron 7, and EWS introns 7, 8, and 9. Prognosis in general is poor, but tumors are responsive to aggressive therapy. CONCLUSION: This large review identifies a greater degree of clinical, pathologic, and molecular variation than originally appreciated for tumors associated with t(11;22)(p13;q12). Translocation and functional fusion of the EWS and WT1 genes appears to be a consistent feature of this unique tumor.

1 September 2018 in Gastroenterology
Verified
Journal Article
Open access
PDF file
MRMatthew D. Rutter
Matthew D. Rutter
IBIosif Beintaris
Iosif Beintaris
RVRoland Valori
Roland Valori
HCHan Mo Chiu
Han Mo Chiu
DCDouglas A. Corley
Douglas A. Corley
SSSilvia Sanduleanu
Silvia Sanduleanu
Although colonoscopy is pivotal for the diagnosis and prevention of colorectal cancer (CRC), cancers can be diagnosed months or years after a colonoscopy that is negative for CRC or CRC precursor lesions.

14 August 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
FBFrancesc Balaguer
Francesc Balaguer
Alexander LinkAlexander Link
Alexander Link
JLJuan Jose Lozano
Juan Jose Lozano
Miriam CuatrecasasMiriam Cuatrecasas
Miriam Cuatrecasas
TNTakeshi Nagasaka
Takeshi Nagasaka
AGAjay Goel
Ajay Goel
Global downregulation of microRNAs (miRNA) is a common feature in colorectal cancer (CRC). Whereas CpG island hypermethylation constitutes a mechanism for miRNA silencing, this field largely remains unexplored. Herein, we describe the epigenetic regulation of miR-137 and its contribution to colorectal carcinogenesis. We determined the methylation status of miR-137 CpG island in a panel of six CRC cell lines and 409 colorectal tissues [21 normal colonic mucosa from healthy individuals (N-N), 160 primary CRC tissues and their corresponding normal mucosa (N-C), and 68 adenomas]. TaqMan reverse transcription-PCR and in situ hybridization were used to analyze miR-137 expression. In vitro functional analysis of miR-137 was performed. Gene targets of miR-137 were identified using a combination of bioinformatic and transcriptomic approaches. We experimentally validated the miRNA:mRNA interactions. Methylation of the miR-137 CpG island was a cancer-specific event and was frequently observed in CRC cell lines (100%), adenomas (82.3%), and CRC (81.4%), but not in N-C (14.4%; P < 0.0001 for CRC) and N-N (4.7%; P < 0.0001 for CRC). Expression of miR-137 was restricted to the colonocytes in normal mucosa and inversely correlated with the level of methylation. Transfection of miR-137 precursor in CRC cells significantly inhibited cell proliferation. Gene expression profiling after miR-137 transfection discovered novel potential mRNA targets. We validated the interaction between miR-137 and LSD-1. Our data indicate that miR-137 acts as a tumor suppressor in the colon and is frequently silenced by promoter hypermethylation. Methylation silencing of miR-137 in colorectal adenomas suggests it to be an early event, which has prognostic and therapeutic implications. Cancer Res; 70(16); 6609–18. ©2010 AACR.